Jazz Pharmaceuticals (JAZZ) Research & Development (2010 - 2026)

Jazz Pharmaceuticals' Research & Development history runs 17 years deep, the most recent figure standing at $196.0 million for Q1 2026.

• In Q1 2026, Research & Development rose 8.47% year-over-year to $196.0 million; the TTM figure through Mar 2026 stood at $798.1 million (down 5.2% YoY), while the FY2025 annual figure was $782.7 million, down 11.46% from the prior year.
• Research & Development was $196.0 million for Q1 2026 at Jazz Pharmaceuticals, down from $213.9 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $240.5 million in Q4 2024 to a low of $130.0 million in Q1 2022.
• Historically, Research & Development has averaged $194.3 million across 5 years, with a median of $198.2 million in 2025.
• The sharpest annual moves came in 2022 and 2025: Research & Development soared 69.75% in 2022, then retreated 18.91% in 2025.
• A 5-year view of Research & Development shows it stood at $172.6 million in 2022, then grew by 25.53% to $216.6 million in 2023, then advanced by 11.03% to $240.5 million in 2024, then fell by 11.06% to $213.9 million in 2025, then fell by 8.37% to $196.0 million in 2026.
• The last three Research & Development figures came in at $196.0 million (Q1 2026), $213.9 million (Q4 2025), and $198.2 million (Q3 2025), per Business Quant data.